In hepatocellular carcinoma (HCC), silencing METTL3 and METTL14 has been shown to reduce the level of circRNA-SORE, which acts as a miRNA sponge by recruiting miR-103a-2-5p and miR-660-3p to competitively activate the Wnt/β-catenin pathway, thereby inducing sorafenib resistance [42]. This evidence concerns the gene METTL14 and hepatocellular carcinoma.